The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Potential predictive and prognostic factors for sequential treatment with abiraterone acetate and cabazitaxel in metastatic docetaxel-refractory castration-resistant prostate cancer (mDR-CRPC).
Sergio Bracarda
Consultant or Advisory Role - Janssen-Ortho; Sanofi
Honoraria - Janssen-Ortho; Sanofi
Alketa Hamzaj
No relevant relationships to disclose
Michele Sisani
No relevant relationships to disclose
Giuseppe Di Lorenzo
Consultant or Advisory Role - Janssen-Ortho
Francesca Marrocolo
No relevant relationships to disclose
Sabrina del Buono
No relevant relationships to disclose
Valeria de Simone
No relevant relationships to disclose
Verena De Angelis
No relevant relationships to disclose